Skip to main content
. 2019 May 10;21(8):1143–1144. doi: 10.1093/europace/euz132

Table 8.

Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis

Study N LVEF, % Concurrent immunosuppressive therapy, n (%) VTs induced, mean ± SD Mapping, Endo n/Epi n Ablation, Endo n/Epi n Patients undergoing repeated procedures, n (%) VT recurrence, n (%) VT burden decrease, n (%) Major complications Follow-up, months
Koplan et al. (S9.12.26) 8 35 ± 15 5 (63) 4 ± 2 6/2 8/2 1 (13) 6 (75) 4 (44) NR 6
Jefic et al. (S9.12.15) 9 42 ± 14 8 (89) 5 ± 7 8/1 NR 3 (33) 4 (44) 9 (100) NR 20
Naruse et al. (S9.12.24) 14 40 ± 12 12 (86) 3 ± 1 14/0 14/0 4 (29) 6 (43) NR NR 33
Dechering et al. (S9.12.12) 8 36 ± 19 NR 4 ± 2 NR NR NR 1 (13) 7 (88) NR 6
Kumar et al. (S9.12.27) 21 36 ± 14 12 (57) Median 3 (range 1–8) 21/8 21/5 11 (52) 15 (71) 16 (76) 4.7% 24
Muser et al. (S9.12.25) 31 42 ± 15 22 (71) Median 3 (range 1–5) 31/11 31/8 9 (29) 16 (52) 28 (90) 4.5% 30

LVEF = left ventricular ejection fraction; N = number; NR = not reported; VT = ventricular tachycardia.